Drugs / Insulin Peglispro
Insulin Peglispro
English name insulin peglispro
Protein / enzyme biologic targets INSR via activation
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT02197520 | Jul 2014 → Jun 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02152384 | Jun → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02109029 | Apr 2014 → Mar 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01995526 | Dec 2013 → Jan 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01925989 | Nov 2013 → Oct 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01771250 | Oct 2013 → Dec 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01871493 | Jun → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01877265 | Jun → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01818245 | Mar → Jul 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01769404 | Feb → Dec 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01784211 | Feb → Nov 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01751399 | Dec 2012 → Sep 2013 | liver disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01654380 | Jul 2012 → Oct 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01027871 | Jan → Dec 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01049412 | Jan → Dec 2010 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT02106364 | Feb → Nov 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 3 | NCT02132637 | May 2014 → Jul 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01894568 | Jul 2013 → Apr 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01790438 | Mar 2013 → May 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01792284 | Feb 2013 → Apr 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01582451 | May 2012 → May 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01454284 | Jan 2012 → Feb 2014 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01481779 | Jan 2012 → May 2013 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01468987 | Dec 2011 → Aug 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01435616 | Nov 2011 → Jan 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03025009 Comparator | Mar 2017 → Apr 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin peglispro | “Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This...” PMID 29167192 ↗ Nov 20179“Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods.” NCT01925989 ↗ |
| Known as | Basal Insulin Peglispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03025009 ↗ |
| Known as | BIL | “Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This...” PMID 29167192 ↗ Nov 2017 |
| Known as | Insulina peglispro | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108569 ↗ |
| Known as | Insuline peglispro | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108569 ↗ |
| Known as | LY2605541 | “Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods.” NCT01925989 ↗17“A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus” NCT02106364 ↗ |
| Action | Activate | “Insulin receptor agonist” CHEMBL2108569 ↗ |
| Modality | Protein / enzyme biologic | “novel long-acting basal insulin analog LY2605541” PMID 24198302 ↗ Nov 2013 |
| Route | Subcutaneous | “subcutaneous injection of LY2605541” NCT01027871 ↗ |
| Target | INSR | “Insulin receptor agonist” CHEMBL2108569 ↗ |